Cargando…

Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro

BACKGROUND: Enterococcus faecalis is a bacterium frequently isolated after failed root canal therapy. This study analyzed the antibacterial and antibiofilm effects in vitro of sustained-release fillers (SRF) containing cetylpyridinium chloride (CPC) against vancomycin resistant E. faecalis. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Funk, Bernhard, Kirmayer, David, Sahar-Heft, Sharonit, Gati, Irith, Friedman, Michael, Steinberg, Doron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700812/
https://www.ncbi.nlm.nih.gov/pubmed/31429746
http://dx.doi.org/10.1186/s12903-019-0879-1
_version_ 1783444936960507904
author Funk, Bernhard
Kirmayer, David
Sahar-Heft, Sharonit
Gati, Irith
Friedman, Michael
Steinberg, Doron
author_facet Funk, Bernhard
Kirmayer, David
Sahar-Heft, Sharonit
Gati, Irith
Friedman, Michael
Steinberg, Doron
author_sort Funk, Bernhard
collection PubMed
description BACKGROUND: Enterococcus faecalis is a bacterium frequently isolated after failed root canal therapy. This study analyzed the antibacterial and antibiofilm effects in vitro of sustained-release fillers (SRF) containing cetylpyridinium chloride (CPC) against vancomycin resistant E. faecalis. METHODS: First, the solidification capability was tested by introducing liquid SRF into phosphate buffered saline, followed by 30 s of vortexing. The antimicrobial effects of SRF-CPC against static monospecies biofilms were analyzed with a metabolic assay. Inhibition of biofilm formation was tested by exposing daily refreshed E. faecalis suspensions to SRF-CPC for 9 weeks. To evaluate the effects of SRF-CPC against preformed biofilms, biofilms were grown for 1, 3 and 7 days, and then treated with SRF-CPC for 24 h. Biofilm kill time was tested by applying SRF-CPC to a 3-day-old biofilm and measuring its viability at different time points. All experiments were compared to Placebo SRFs and to untreated control biofilms. Data were analyzed with two-way ANOVA followed by Tukey’s test. Results were considered significant at P < 0.05. RESULTS: The liquid SRF solidified within seconds and no structural changes were observed after 30 s of vortexing at maximum speed. SRF-CPC inhibited E. faecalis biofilm formation for 7 weeks and significantly reduced its viability in weeks 8 and 9. Mature biofilms grown for 1, 3 and 7 days were destructed by SRF-CPC in less than 24 h. Fifty percent of a 3-day-old biofilm was destructed in 2 h and complete destruction occurred in less than 12 h. (P < 0.05 in all cases, compared to SRII-Placebo). CONCLUSIONS: SRF-CPC’s physical properties and long-lasting anti-biofilm effects make it a promising coadjuvant medication for endodontic therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12903-019-0879-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6700812
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67008122019-08-26 Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro Funk, Bernhard Kirmayer, David Sahar-Heft, Sharonit Gati, Irith Friedman, Michael Steinberg, Doron BMC Oral Health Research Article BACKGROUND: Enterococcus faecalis is a bacterium frequently isolated after failed root canal therapy. This study analyzed the antibacterial and antibiofilm effects in vitro of sustained-release fillers (SRF) containing cetylpyridinium chloride (CPC) against vancomycin resistant E. faecalis. METHODS: First, the solidification capability was tested by introducing liquid SRF into phosphate buffered saline, followed by 30 s of vortexing. The antimicrobial effects of SRF-CPC against static monospecies biofilms were analyzed with a metabolic assay. Inhibition of biofilm formation was tested by exposing daily refreshed E. faecalis suspensions to SRF-CPC for 9 weeks. To evaluate the effects of SRF-CPC against preformed biofilms, biofilms were grown for 1, 3 and 7 days, and then treated with SRF-CPC for 24 h. Biofilm kill time was tested by applying SRF-CPC to a 3-day-old biofilm and measuring its viability at different time points. All experiments were compared to Placebo SRFs and to untreated control biofilms. Data were analyzed with two-way ANOVA followed by Tukey’s test. Results were considered significant at P < 0.05. RESULTS: The liquid SRF solidified within seconds and no structural changes were observed after 30 s of vortexing at maximum speed. SRF-CPC inhibited E. faecalis biofilm formation for 7 weeks and significantly reduced its viability in weeks 8 and 9. Mature biofilms grown for 1, 3 and 7 days were destructed by SRF-CPC in less than 24 h. Fifty percent of a 3-day-old biofilm was destructed in 2 h and complete destruction occurred in less than 12 h. (P < 0.05 in all cases, compared to SRII-Placebo). CONCLUSIONS: SRF-CPC’s physical properties and long-lasting anti-biofilm effects make it a promising coadjuvant medication for endodontic therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12903-019-0879-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-20 /pmc/articles/PMC6700812/ /pubmed/31429746 http://dx.doi.org/10.1186/s12903-019-0879-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Funk, Bernhard
Kirmayer, David
Sahar-Heft, Sharonit
Gati, Irith
Friedman, Michael
Steinberg, Doron
Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro
title Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro
title_full Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro
title_fullStr Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro
title_full_unstemmed Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro
title_short Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro
title_sort efficacy and potential use of novel sustained release fillers as intracanal medicaments against enterococcus faecalis biofilm in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700812/
https://www.ncbi.nlm.nih.gov/pubmed/31429746
http://dx.doi.org/10.1186/s12903-019-0879-1
work_keys_str_mv AT funkbernhard efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro
AT kirmayerdavid efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro
AT saharheftsharonit efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro
AT gatiirith efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro
AT friedmanmichael efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro
AT steinbergdoron efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro